WallStreetZenWallStreetZen

NASDAQ: PSTV
Plus Therapeutics Inc Stock

$2.12-0.11 (-4.93%)
Updated Dec 8, 2023
PSTV Price
$2.12
Fair Value Price
$2.49
Market Cap
$9.59M
52 Week Low
$0.97
52 Week High
$7.20
P/E
-0.35x
P/B
3.66x
P/S
1.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.75M
Earnings
-$15.16M
Gross Margin
100%
Operating Margin
-391.15%
Profit Margin
-404.3%
Debt to Equity
4.06
Operating Cash Flow
-$13M
Beta
1.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

PSTV Overview

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PSTV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PSTV ($2.12) is undervalued by 14.71% relative to our estimate of its Fair Value price of $2.49 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PSTV ($2.12) is not significantly undervalued (14.71%) relative to our estimate of its Fair Value price of $2.49 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PSTV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PSTV due diligence checks available for Premium users.

Be the first to know about important PSTV news, forecast changes, insider trades & much more!

PSTV News

Valuation

PSTV fair value

Fair Value of PSTV stock based on Discounted Cash Flow (DCF)
Price
$2.12
Fair Value
$2.49
Undervalued by
14.71%
PSTV ($2.12) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PSTV ($2.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PSTV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PSTV price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.35x
Industry
11.7x
Market
31.32x

PSTV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.66x
Industry
5.42x
PSTV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PSTV's financial health

Profit margin

Revenue
$1.2M
Net Income
-$3.2M
Profit Margin
-259.6%
PSTV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PSTV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$13.3M
Liabilities
$10.7M
Debt to equity
4.06
PSTV's short-term assets ($11.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PSTV's short-term assets ($11.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PSTV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PSTV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.4M
Investing
-$10.0k
Financing
$2.5M
PSTV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PSTV vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
PSTV$9.59M-4.93%-0.35x3.66x
GOVX$9.61M-7.22%-0.40x1.05x
ARAV$9.56M-2.99%-0.25x5.62x
BCEL$9.55M-8.37%-0.10x0.89x
TNXP$9.49M+4.74%-0.04x0.08x

Plus Therapeutics Stock FAQ

What is Plus Therapeutics's quote symbol?

(NASDAQ: PSTV) Plus Therapeutics trades on the NASDAQ under the ticker symbol PSTV. Plus Therapeutics stock quotes can also be displayed as NASDAQ: PSTV.

If you're new to stock investing, here's how to buy Plus Therapeutics stock.

What is the 52 week high and low for Plus Therapeutics (NASDAQ: PSTV)?

(NASDAQ: PSTV) Plus Therapeutics's 52-week high was $7.20, and its 52-week low was $0.97. It is currently -70.54% from its 52-week high and 118.78% from its 52-week low.

How much is Plus Therapeutics stock worth today?

(NASDAQ: PSTV) Plus Therapeutics currently has 4,522,656 outstanding shares. With Plus Therapeutics stock trading at $2.12 per share, the total value of Plus Therapeutics stock (market capitalization) is $9.59M.

Plus Therapeutics stock was originally listed at a price of $1,320,554.12 in Nov 16, 2000. If you had invested in Plus Therapeutics stock at $1,320,554.12, your return over the last 23 years would have been -100%, for an annualized return of -44.02% (not including any dividends or dividend reinvestments).

How much is Plus Therapeutics's stock price per share?

(NASDAQ: PSTV) Plus Therapeutics stock price per share is $2.12 today (as of Dec 8, 2023).

What is Plus Therapeutics's Market Cap?

(NASDAQ: PSTV) Plus Therapeutics's market cap is $9.59M, as of Dec 11, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Plus Therapeutics's market cap is calculated by multiplying PSTV's current stock price of $2.12 by PSTV's total outstanding shares of 4,522,656.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.